- Home
- RVTY vs EXEL Comparison
RVTY vs EXEL Comparison
Compare RVTY & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RVTY | EXEL |
|---|---|---|
| Founded | 1937 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 11.1B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | RVTY | EXEL |
|---|---|---|
| Price | $95.74 | $43.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 21 |
| Target Price | ★ $113.00 | $46.60 |
| AVG Volume (30 Days) | 1.6M | ★ 2.6M |
| Earning Date | 02-02-2026 | 02-10-2026 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | 2.07 | ★ 2.78 |
| Revenue | ★ $2,856,051,000.00 | $2,320,126,000.00 |
| Revenue This Year | $6.06 | $14.86 |
| Revenue Next Year | $5.15 | $14.93 |
| P/E Ratio | $46.68 | ★ $15.80 |
| Revenue Growth | 3.67 | ★ 6.98 |
| 52 Week Low | $81.36 | $32.38 |
| 52 Week High | $120.39 | $49.62 |
Technical Indicators
Market Signals| Indicator | RVTY | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 38.74 | 51.45 |
| Support Level | $93.70 | $40.92 |
| Resistance Level | $106.55 | $44.28 |
| Average True Range (ATR) | 4.33 | 1.48 |
| MACD | -1.62 | 0.03 |
| Stochastic Oscillator | 15.05 | 70.53 |
Price Performance
Historical ComparisonAbout RVTY Revvity Inc.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.